International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–1
- Intermediate Risk2–3
- High Risk4–6
- Very High Risk7–10
The International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include tp53 status. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Stratifies chronic lymphocytic leukemia patients into four risk categories based on five independent prognostic factors. The CLL-IPI combines genetic (TP53 status, IGHV mutational status), biochemical (β2-microglobulin), and clinical parameters (age, clinical stage) to predict overall survival and treatment outcomes. This validated prognostic model discriminates four risk groups with significantly different 5-year overall survival rates: low risk (93.2%), intermediate risk (79.3%), high risk (63.3%), and very high risk (23.3%). The CLL-IPI enables more targeted patient management and risk-adapted treatment strategies in clinical practice and clinical trials.
Clinical Indication
The International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) is indicated for bedside clinical practice to support Stratifies chronic lymphocytic leukemia patients into four risk categories based on five independent prognostic factors. The CLL-IPI combines genetic (TP53 status, IGHV mutational status), biochemical (β2-microglobulin), and clinical parameters (age, clinical stage) to predict overall survival and treatment outcomes. This validated prognostic model discriminates four risk groups with significantly different 5-year overall survival rates: low risk (93.2%), intermediate risk (79.3%), high risk (63.3%), and very high risk (23.3%). The CLL-IPI enables more targeted patient management and risk-adapted treatment strategies in clinical practice and clinical trials.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: The CLL-IPI predicts overall survival and has been validated for time to first treatment.
Score = TP53 abnormal (4) + IGHV unmutated (2) + β2-microglobulin >3.5mg/L (2) + Advanced stage (1) + Age >65 years (1)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| tp53_status | string | Yes | TP53 gene abnormalities including del(17p) and/or TP53 mutation |
| ighv_status | string | Yes | IGHV (immunoglobulin heavy chain variable) mutational status |
| beta2_microglobulin | string | Yes | Serum β2-microglobulin concentration level(mg/L) |
| clinical_stage | string | Yes | Clinical stage based on Binet or Rai staging systems |
| age | string | Yes | Patient age category(years) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1 | Low Risk | Score 0-1 points |
| 2–3 | Intermediate Risk | Score 2-3 points |
| 4–6 | High Risk | Score 4-6 points |
| 7–10 | Very High Risk | Score 7-10 points |
Evidence-Based References (EBM)
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016 Jul;17(7):779-90. doi: 10.1016/S1470-2045(16)30029-8.DOI: 10.1016/S1470-2045(16)30029-8
- Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 May 28;135(22):1859-1869. doi: 10.1182/blood.2019003453.DOI: 10.1182/blood.2019003453
- Gentile M, Shanafelt TD, Rossi D, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood. 2016 Oct 13;128(15):2093-2095. doi: 10.1182/blood-2016-07-728261.DOI: 10.1182/blood-2016-07-728261
Related calculators
- Binet Staging System for Chronic Lymphocytic Leukemia (CLL)
- International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)
- National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)
- Central Nervous System International Prognostic Index (CNS-IPI)
- International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E)